Zhou, Yitian
Nevosadová, Lenka
Eliasson, Erik
Lauschke, Volker M.
Funding for this research was provided by:
Karolinska Institute
Article History
Received: 4 November 2022
Accepted: 16 February 2023
First Online: 28 February 2023
Declarations
:
: YZ and VML are co-founders and shareholders of PersoMedix AB. In addition, VML is CEO and shareholder of HepaPredict AB. EE is vice-chair of the Genomic Medicine Sweden Pharmacogenomics work package, supported by grants from The Swedish Innovation Agency. EE also received funding from the Stockholm Region (CIMED). The other authors do not disclose competing interests.